Affiliation:
1. Department of Medical Oncology Bakirkoy Dr. Sadi Konuk Training and Research Hospital Istanbul Turkey
2. Department of Medical Oncology Başakşehir Çam and Sakura City Hospital Istanbul Turkey
Abstract
AbstractBackgroundRecurrence develops in 50% of operated bladder cancer patients. It is important to detect recurrence in advance, and there is no prognostic reliable biomarker for bladder cancer.ObjectiveThe aim of this study is to show that changes in hematological parameters before radiological imaging can predict recurrence.MethodsWe performed a retrospective cohort study of patients undergoing radical cystectomy for urothelial carcinoma of the bladder identified using our institutional database (2010–2022). Disease‐free survival (DFS) was evaluated as relapse or death due to any cause. Kaplan‐Meier analysis was used for DFS according to the follow‐up period. DFS was calculated in two groups neutrophil‐lymphocyte ratio (NLR) < 3 and NLR ≥ 3. Log‐rank test was used for comparison between groups and p < 0.05 was considered statistically significant.ResultsIn the study, 91 patients were examined. The median age was 61.0 (34–79). 57.1% of the patients were T (1–2) and 42.9% were T (3–4). The lymph node (LN) was negative in 78% and positive in 22%. Median follow‐up time and DFS were 53.4 months and 54%, respectively. The median NLR was 2.8 (0.8–8.7). For DFS, there was a significant difference according to age, T stage, and LN status (p: 0.048, 0.019, and 0.040). There was no significant difference in the NLR in terms of DFS at the time of diagnosis (p: 0.654). In follow‐ups; While there was no difference in the NLR for DFS 12 months before recurrence (p: 0.231), there was a significant difference 6 months before the relapse and at the time of recurrence (p: 0.023 and 0.031).ConclusionThe change in the NLR before radiological recurrence in bladder cancer is significant in predicting recurrence. Prospective and multi‐center research is needed to confirm our findings.